These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30238648)

  • 1. Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register.
    Lövestam Adrian M; Vassilev ZP; Westborg I
    Acta Ophthalmol; 2019 Feb; 97(1):91-98. PubMed ID: 30238648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register.
    Westborg I; Granstam E; Rosso A; Albrecht S; Karlsson N; Lövestam-Adrian M
    Acta Ophthalmol; 2017 Dec; 95(8):787-795. PubMed ID: 28834299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
    Steinle NC; Du W; Gibson A; Saroj N
    Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
    Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world visual outcomes in patients with neovascular age-related macular degeneration receiving aflibercept at fixed intervals as per UK licence.
    Ozturk M; Harris ML; Nguyen V; Barthelmes D; Gillies MC; Mehta H
    Clin Exp Ophthalmol; 2018 May; 46(4):407-411. PubMed ID: 29044979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degeneration.
    Zhu M; Wijeyakumar W; Syed AR; Joachim N; Hong T; Broadhead GK; Li H; Luo K; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):475-484. PubMed ID: 27572301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.
    Calvo-Gonzalez C; Reche-Frutos J; Fernández-Vigo JI; Donate-López J; Serrano-García I; Fernández-Pérez C
    Int Ophthalmol; 2019 Nov; 39(11):2441-2448. PubMed ID: 30767090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration.
    Saito M; Kano M; Itagaki K; Sekiryu T
    Jpn J Ophthalmol; 2017 Jan; 61(1):74-83. PubMed ID: 27660164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting.
    Eleftheriadou M; Vazquez-Alfageme C; Citu CM; Crosby-Nwaobi R; Sivaprasad S; Hykin P; Hamilton RD; Patel PJ
    Am J Ophthalmol; 2017 Feb; 174():160-168. PubMed ID: 27746298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade.
    Schwartz R; Warwick A; Olvera-Barrios A; Pikoula M; Lee AY; Denaxas S; Taylor P; Egan C; Chakravarthy U; Lip PL; Tufail A;
    Ophthalmol Retina; 2021 Aug; 5(8):e11-e22. PubMed ID: 33866023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group.
    Almuhtaseb H; Johnston RL; Talks JS; Lotery AJ
    Eye (Lond); 2017 Nov; 31(11):1582-1588. PubMed ID: 28622328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
    Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
    Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Barthelmes D; Nguyen V; Daien V; Campain A; Walton R; Guymer R; Morlet N; Hunyor AP; Essex RW; Arnold JJ; Gillies MC;
    Retina; 2018 Jan; 38(1):20-28. PubMed ID: 28145976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
    Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
    Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
    Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia.
    Jaki Mekjavić P; Gregorčič B; Oberč C; Podgoršek S
    BMC Ophthalmol; 2018 Dec; 18(1):333. PubMed ID: 30572850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.